Alkeus Pharmaceuticals Inc.

Cambridge, MA

UEI
MQZNHQ1FW6M3
CAGE
5XDB0
Primary NAICS
325412 Pharmaceutical Preparation Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
44 Brattle St # 2, Cambridge, MA 02138, USA
Website
alkeuspharma.com
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
ALK-001 phase 2 treatment of stargardt disease IND 108,353 (09/08/2015) R01FD006316 FDA Office of Acquisition and Grant Services $2,750,000
Phase 1 study of ALK001 for stargardt disease R01FD004098 Food and Drug Administration $415,984
A phase 2A clinical trial of ALK-001 in geographic atrophy R44EY021988 National Eye Institute (NIH) $2,086,555
Phase 1 safety and pharmacokinetics of ALK001 in people over 60 R41EY021988 National Institutes of Health $165,198

Quick answers

Is Alkeus Pharmaceuticals Inc. registered in SAM.gov?

Yes. Alkeus Pharmaceuticals Inc.'s SAM.gov registration is active through November 27, 2026.

What is Alkeus Pharmaceuticals Inc.'s most recent federal award?

Alkeus Pharmaceuticals Inc.'s most recent federal grant award is ALK-001 phase 2 treatment of stargardt disease IND 108,353 (09/08/2015) (R01FD006316), from FDA Office of Acquisition and Grant Services, on July 1, 2018.

On GovTribe

See Alkeus Pharmaceuticals Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login